Labcorp Holdings Inc. (LH) Stock Analysis
Recovery setup
Healthcare · Diagnostics & Research
Sell if holding. Momentum 3.5/10 is below the 5.0 floor at $256.63 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Thin upside margin: 8.9%; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.9).
Labcorp Holdings is a global laboratory services company operating two segments: Dx (diagnostic testing, $10.9B revenue in 2025) and BLS (biopharma lab services, $3.1B), serving patients, healthcare providers, and pharmaceutical companies in ~100 countries. Revenue is generated... Read more
Sell if holding. Momentum 3.5/10 is below the 5.0 floor at $256.63 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Thin upside margin: 8.9%; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.9). Chart setup: Death cross but MACD improving, RSI 49. Score 5.4/10, moderate confidence.
Passes 6/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 64d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: moderate.
Recent Developments — Labcorp Holdings Inc.
Latest news
- What To Expect From Labcorp’s (LH) Q1 Earnings - StockStory — StockStory neutral
- LH (Labcorp Holdings Inc.) delivers 7.2% YoY Q4 2025 revenue growth and small EPS beat, shares edge down 0.8%. - Expert — Cổng thông tin điện tử tỉnh Tây Ninh positive
- All you need to know about Labcorp (LH) rating upgrade to buy - MSN — MSN positive
- Evercore ISI Group Raises Labcorp Holdings (LH) Price Target to $300 | LH Stock News - GuruFocus — GuruFocus positive
- Raleigh Capital Management Inc. Sells 11,248 Shares of Labcorp Holdings Inc. $LH - MarketBeat — MarketBeat neutral
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 3.5/10 is below the 5.0 floor at $256.63 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Thin upside margin: 8.9%; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.9). Chart setup: Death cross but MACD improving, RSI 49. Prior stop was $245.13. Score 5.4/10, moderate confidence.
Take-profit target: $279.11 (+8.9% upside). Prior stop was $245.13. Stop-loss: $245.13.
Thin upside margin: 8.9%; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.9); Negative momentum.
Labcorp Holdings Inc. trades at a P/E of 22.5 (forward 13.0). TrendMatrix value score: 6.9/10. Verdict: Sell.
29 analysts cover LH with a consensus score of 4.1/5. Average price target: $310.
What does Labcorp Holdings Inc. do?Labcorp Holdings is a global laboratory services company operating two segments: Dx (diagnostic testing, $10.9B revenue...
Labcorp Holdings is a global laboratory services company operating two segments: Dx (diagnostic testing, $10.9B revenue in 2025) and BLS (biopharma lab services, $3.1B), serving patients, healthcare providers, and pharmaceutical companies in ~100 countries. Revenue is generated from test fees billed to MCOs, Medicare/Medicaid, clients, and patients, with nearly all Dx revenues from the U.S. and BLS split 41%/59% U.S./international.